Immunological Facet and Inception after Post-COVID-19 Vaccination.

Q3 Pharmacology, Toxicology and Pharmaceutics Infectious disorders drug targets Pub Date : 2023-01-01 DOI:10.2174/1871526523666230406100146
Suman Kumar Ray, Sukhes Mukherjee
{"title":"Immunological Facet and Inception after Post-COVID-19 Vaccination.","authors":"Suman Kumar Ray,&nbsp;Sukhes Mukherjee","doi":"10.2174/1871526523666230406100146","DOIUrl":null,"url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced coronavirus disease 2019 (COVID-19) pandemic has produced an unparalleled setback for the world's economy and health. One of the best therapies to significantly lower severe illness and mortality from SARS-CoV-2 infection is vaccination. Worldwide vaccination campaigns are being implemented. New-onset autoimmune problems, such as immune thrombotic thrombocytopenia, autoimmune liver disorders, IgA nephropathy, Guillain-Barré syndrome, systemic lupus erythematosus, and rheumatoid arthritis, have recently been described more frequently after receiving COVID-19 vaccine. The creation of specific autoantibodies, molecular mimicry, and the function of specific vaccine adjuvants all emerge to play a significant role in autoimmunity. The post-acute sequelae of SARS-CoV-2, usually known as Long Covid Syndrome, are beginning to be better understood in terms of the disparities in immune responses seen in individuals with and without the condition. We anticipate that the knowledge gleaned from several COVID-19 investigations will be put to use in research on the inflammatory mechanisms implicated in serious and protracted illnesses, which is still a key unmet need.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 5","pages":"e060423215496"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526523666230406100146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced coronavirus disease 2019 (COVID-19) pandemic has produced an unparalleled setback for the world's economy and health. One of the best therapies to significantly lower severe illness and mortality from SARS-CoV-2 infection is vaccination. Worldwide vaccination campaigns are being implemented. New-onset autoimmune problems, such as immune thrombotic thrombocytopenia, autoimmune liver disorders, IgA nephropathy, Guillain-Barré syndrome, systemic lupus erythematosus, and rheumatoid arthritis, have recently been described more frequently after receiving COVID-19 vaccine. The creation of specific autoantibodies, molecular mimicry, and the function of specific vaccine adjuvants all emerge to play a significant role in autoimmunity. The post-acute sequelae of SARS-CoV-2, usually known as Long Covid Syndrome, are beginning to be better understood in terms of the disparities in immune responses seen in individuals with and without the condition. We anticipate that the knowledge gleaned from several COVID-19 investigations will be put to use in research on the inflammatory mechanisms implicated in serious and protracted illnesses, which is still a key unmet need.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
covid -19疫苗接种后的免疫学方面和初始阶段。
2019年严重急性呼吸系统综合征(SARS-CoV-2)引发的冠状病毒病(COVID-19)大流行给世界经济和健康带来了前所未有的挫折。显著降低SARS-CoV-2感染导致的严重疾病和死亡率的最佳疗法之一是接种疫苗。正在实施世界范围的疫苗接种运动。新发自身免疫性问题,如免疫性血栓性血小板减少症、自身免疫性肝病、IgA肾病、格林-巴罗综合征、系统性红斑狼疮和类风湿性关节炎,最近在接种COVID-19疫苗后被描述得更为频繁。特异性自身抗体的产生、分子模仿和特异性疫苗佐剂的功能都在自身免疫中发挥重要作用。SARS-CoV-2的急性后后遗症,通常被称为长冠综合征,从患者和非患者的免疫反应差异来看,人们开始更好地了解这种疾病。我们预计,从几项COVID-19调查中收集到的知识将用于研究与严重和长期疾病有关的炎症机制,这仍然是一个未得到满足的关键需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Infectious disorders drug targets
Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
3.10
自引率
0.00%
发文量
123
期刊介绍: Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
期刊最新文献
Vigilance Needed in Treating a Child with Disseminated TB: A Case Report. Vitamin D and Mitochondrial Activity Preservation in COVID-19. Recombinant ACE2 - Opportunities and Challenges in COVID-19 Treatment. Outbreak and Management Strategies of Nipah Virus: A Scenario from the Southern Part of India. A Day Saved is a Life Saved: Direct Antimicrobial Susceptibility Testing from Positively Flagged Blood Culture Bottles and their Concordance with the Routine Method.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1